遗传性抗凝血酶缺乏症患者的治疗策略
本文综述遗传性抗凝血酶(AT)缺乏症的临床管理,该病为少见但血栓风险较高的遗传性易栓症,尤其1型定量缺乏者可在早年发生血栓,女性因口服避孕药或妊娠风险进一步升高。由于缺乏对照试验或大样本观察研究,治疗决策无法基于科学证据,本文讨论血栓表现病例及个体化管理。
要点
- 遗传性AT缺乏症是少见但血栓风险较高的易栓症,1型定量缺乏者风险更高。
- 女性使用雌孕激素口服避孕药或妊娠可显著增加血栓风险。
- 缺乏对照试验或大样本观察研究,治疗决策需个体化。
核心结论
- 遗传性AT缺乏症患者血栓风险较高,尤其1型定量缺乏者,但缺乏高质量证据指导治疗决策。
研究设计与样本
- 本文为叙述性综述,讨论遗传性AT缺乏症患者的血栓表现及个体化管理。
主要发现
- 先天性AT缺乏症是少见的遗传性静脉血栓栓塞(VTE)危险因素,不同亚型血栓风险不同。
- 1型定量缺乏患者可能在早年发生血栓,且常有第一、二级亲属VTE家族史。
- 女性因雌孕激素口服避孕药或妊娠导致风险进一步升高。
临床怎么用
- 对遗传性AT缺乏症患者应进行个体化管理,尤其关注女性避孕和妊娠相关血栓风险。
局限性
- 缺乏对照试验或大样本观察研究,无法基于科学证据做出治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic predispositions to venous thromboembolism (VTE) are relatively frequent in the general population and comprise a heterogeneous group of disorders. Whereas the most frequent congenital risk factors for thrombosis only moderately increase the risk, a deficiency in antithrombin (AT), one of the most important natural inhibitors of blood coagulation, carries a higher risk. Congenital AT deficiency is an infrequently encountered genetic risk factor for VTE, and different subtypes vary with regard to their thrombotic risk. Patients with congenital AT deficiency, especially those with quantitative deficiency (type 1), may develop thrombosis early in life and often have a conspicuous family history of first- and second-degree relatives with VTE. Women are particularly affected because of the risk potentiation by combined estrogen/progestogen oral contraceptive use or pregnancy. The lack of controlled trials or even observational studies of large cohorts does not allow therapeutic decisions to be based on scientific evidence. In this review, we will discuss cases with thrombotic manifestations and the tailored management of patients with this congenital thrombosis risk factor.
引用
- Pabinger I, Thaler J. How I treat patients with hereditary antithrombin deficiency. Blood. 2019. PMID: 31697819. doi:10.1182/blood.2019002927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。